Q3 EPS Estimates for Oncobiologics Boosted by Analyst

Oncobiologics, Inc. (NASDAQ:OTLK) – Investment analysts at Ascendiant Capital Markets raised their Q3 2026 earnings per share (EPS) estimates for Oncobiologics in a research note issued to investors on Tuesday, June 9th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will post earnings of ($0.10) per share for the quarter, up from their previous forecast of ($0.14). Ascendiant Capital Markets currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Oncobiologics’ current full-year earnings is ($0.48) per share. Ascendiant Capital Markets also issued estimates for Oncobiologics’ Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.51) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.33) EPS.

Oncobiologics (NASDAQ:OTLK) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The firm had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $4.39 million.

Other analysts also recently issued reports about the company. Wall Street Zen upgraded Oncobiologics to a “sell” rating in a research report on Saturday, May 30th. BTIG Research restated a “neutral” rating on shares of Oncobiologics in a report on Monday, May 18th. HC Wainwright reaffirmed a “neutral” rating on shares of Oncobiologics in a research note on Wednesday, February 18th. Chardan Capital reiterated a “neutral” rating on shares of Oncobiologics in a report on Wednesday, February 18th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Oncobiologics in a research report on Friday, March 27th. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $6.50.

Oncobiologics Price Performance

OTLK opened at $1.22 on Monday. The business has a fifty day moving average of $0.41 and a 200 day moving average of $0.72. The stock has a market cap of $170.86 million, a P/E ratio of -1.04 and a beta of 0.94. Oncobiologics has a 52-week low of $0.16 and a 52-week high of $3.39.

Insiders Place Their Bets

In other news, Director Ghiath M. Sukhtian bought 8,539,709 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was acquired at an average cost of $0.59 per share, with a total value of $5,038,428.31. Following the transaction, the director directly owned 22,092,068 shares in the company, valued at approximately $13,034,320.12. This trade represents a 63.01% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Oncobiologics

Institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. increased its stake in shares of Oncobiologics by 865.2% during the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after buying an additional 21,941 shares during the period. AQR Capital Management LLC lifted its stake in Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock worth $103,000 after acquiring an additional 25,351 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after acquiring an additional 44,063 shares in the last quarter. Hedge funds and other institutional investors own 11.20% of the company’s stock.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.